Genmab — November 2017
-
Tænker jeg os Bulder,
-
PR og muligheden for at søge på interimdata - så bliver det vist ikke meget mere høj-prioriteret fra FDAs side, når vi taler 1.line
-
Jeg tænker på at får vi Japan salget i gang i f.eks. 1. halvdel af december, så vil det da bidrage positivt til en eventuel blød opjustering. Det vil godt nok komme efter q3 regnskabet, men det vil blive opfattet positivt. Sidste år kom der en sen opjustering pga. noget lignende.
-
Another death related to allogenic CAR-T cell therapy https://european-biotechnology.com/up-to-date/latest-news/news/another-death-related-to-allogenic-car-t-cell-therapy.html
-
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind

